Greenberg Traurig LLP counsels innovative life sciences companies in the biotech, pharma, medical devices, and healthcare sectors. It handles regulatory and transactional matters, while being particularly strong in IP. The team advises on IP portfolio management and diligence, litigation, and sale internationally, with ‘excellent knowledge’ across jurisdictions. The practice is co-headed by Boston-based patent attorney David Dykeman, focused on securing worldwide IP protection, and Atlanta’s Wayne Elowe, who concentrates on worldwide corporate counseling and complex commercial transactions, such as M&A, licensing and joint ventures. Melissa Hunter-Ensor, in Boston, experienced in IP portfolio management, strategic alliances, and litigation strategy, is a key figure in the practice. Chia-Feng Lu, based in Washington DC and Tokyo, applies his ’strategic thinking’ to regulatory and transactional law.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘The team's people, attention to detail, knowledge of the technology and business sense is what sets them apart from other firms in the life sciences practice. The team has consistently exceeded expectations with their knowledge and responsiveness.’
‘GT has the unique ability to understand a client's technology, understand the client's strategy to create significant value and provide specific and high quality legal services to support this strategy. GT has strength across the various aspects of Life Sciences legal services, including patent/IP protection, regulatory, reimbursement, digital, etc., and experience in pharma, devices, and digital, which makes it quite powerful and great to work with. The quality of its lawyers in each area is outstanding.’
‘The team functions like a well-lubricated machine. From the partners through the paraprofessionals, everyone is knowledgable about our needs and is very responsive.’
- ‘The team has a great coverage with excellent knowledge of various countries and regions, including the US, China, Japan and Europe.’
‘Chia-Feng Lu has impressed me and my board with his strategic thinking and proactiveness in addressing potential opportunities and risks. When working on our ongoing cases, he spent time and made an effort to understand the background of the companies and assets, as well as our intention. He analyzed the scenarios and potential approaches to meet our objectives at the kick-off. He helped craft oral and written communication to ensure the precision and control the pace of the interaction/negotiation.’
‘Dave Dykeman is a masterful head of the healthcare practice and is able to pull the requisite people/resources/connections to make anything happen. He ensures phenomenal service to his clients. One cannot ask for better.’
Key clients
- Provention Bio, Inc.
- Micron Biomedical
- V-Wave Ltd.
- Amneal Pharmaceuticals LLC
- Bausch and Lomb Corp./Novartis AG
- Aspira Women’s Health (formerly Vermillion)
- Renzoku Biologics K.K.
- JenaValve Technology
- Embecta Corp.
- Exactech, Inc.
- Fate Therapeutics, Inc
- Redhill Biopharma
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Next Generation Partners
Junior partners with significant recognition from clients and peers in the market and key roles on multiple matters.
Chia-Feng Lu
Practice head
David Dykeman; Wayne Elowe
Other key lawyers
Lori Cohen; Melissa Hunter-Ensor; Jonathan Ball; Chia-Feng Lu; David Harburger; Prashant Girinath; Jeffrey C. Giering; Micheal Hebert; Roman Fayerberg